Suspension Of Amorphous Calcium Phosphate Nanoparticles Impact Commitment Of Human Adipose-Derived Stem Cells In Vitro

Simple Summary Calcium phosphate is an important component in natural bone. Bone defects caused by trauma or resection of tumors demand bone substitutes to close the defect. One viable option is to use a scaffold material seeded with stem cells. Stem cells can differentiate towards bone cells (osteoblasts), among other cell types. To trigger stem cells towards the osteoblast type of cell, particular supplementation of the culture medium is needed. This study tests whether calcium phosphate nanoparticles can induce a commitment towards the osteoblast type of cell. In addition, we test for other commitments, such as endothelial cell, chondrocyte, or adipocyte commitment. After 1 or 2 weeks, with either 5 or 50 mu g/mL nanoparticles in the culture medium, gene expression is analyzed. We find a significant increase of two specific bone marker genes after two weeks in 50 mu g/mL nanoparticles compared to 5 mu g/mL for two out of three tested human donors of adipose-derived stem cells. Moreover, endothelial cell commitment is also induced. Hence, such nanoparticles have the potential to trigger osteogenic and endothelial cell commitment. Amorphous calcium phosphate (aCaP) nanoparticles may trigger the osteogenic commitment of adipose-derived stem cells (ASCs) in vitro. The ASCs of three human donors are investigated using basal culture medium DMEM to either 5 or 50 mu g/mL aCaP nanoparticles suspension (control: no nanoparticles). After 7 or 14 days, stem cell marker genes, as well as endothelial, osteogenic, chondrogenic, and adipogenic genes, are analyzed by qPCR. Free calcium and phosphate ion concentrations are assessed in the cell culture supernatant. After one week and 5 mu g/mL aCaP, downregulation of osteogenic markers ALP and Runx2 is found, and averaged across the three donors. Our results show that after two weeks, ALP is further downregulated, but Runx2 is upregulated. Endothelial cell marker genes, such as CD31 and CD34, are upregulated with 50 mu g/mL aCaP and a 2-week exposure. Inter-donor variability is high: Two out of three donors show a significant upregulation of ALP and Runx2 at day 14 with 50 mu g/mL aCaP compared to 5 mu g/mL aCaP. Notably, all changes in stem cell commitment are obtained in the absence of an osteogenic medium. While the chemical composition of the culture medium and the saturation status towards calcium phosphate phases remain approximately the same for all conditions, gene expression of ASCs changes considerably. Hence, aCaP nanoparticles show the potential to trigger osteogenic and endothelial commitment in ASCs.